铜绿假单胞菌噬菌体治疗的研究进展

Progress on Pseudomonas aeruginosa bacteriophage therapy

噬菌体是专门裂解细菌的病毒,有望用于治疗超级耐药细菌感染。截止2017年1月10日,Pub Med数据库共存有1900多株噬菌体基因组序列,其中铜绿假单胞菌噬菌体为202株,约占所有测序噬菌体的十分之一。铜绿假单胞菌是临床中最常见的条件致病菌之一,且抗生素耐药情况日趋严重。2017年2月,世界卫生组织将铜绿假单胞菌列为迫切需要新型抗生素来治疗的超级细菌之一。因此,铜绿假单胞菌噬菌体及其治疗耐药菌感染的研究备受关注。本文先就铜绿假单胞菌噬菌体的研究情况进行分析,然后对铜绿假单胞菌噬菌体治疗现状进行综述。

Bacteriophages are viruses that specifically infect bacteria and are expected to be used to treat antibiotic resistant bacterial infections. As of January 10, 2017, the PubMed database has deposited more than 1,900 phage genome sequences, of which 202 were Pseudomonas aeruginosa phages, accounting for about one tenth of all sequenced phages. Pseudomonas aeruginosa is one of the most common opportunistic pathogens in clinics, which infects cystic fibrosis patients, cancer patients and other immune-compromised individuals. Recently, the antibiotic resistance of Pseudomonas aeruginosa is becoming more and more serious. February 2017, the World Health Organization listed Pseudomonas aeruginosa as one of the most important pathogens that need new antibiotics to treat. Therefore, phages have become a promising alternative to treat antibiotic resistant bacteria. Here, we reviewed the progress on Pseudomonas aeruginosa phages based on the sequence data and Pseudornonas aeruginosa phage therapy.